Ocuphire Pharma Inc (NASDAQ: OCUP)’s stock price has gone rise by 12.20 in comparison to its previous close of 1.64, however, the company has experienced a 19.87% increase in its stock price over the last five trading days. InvestorPlace reported 2024-02-26 that While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
Is It Worth Investing in Ocuphire Pharma Inc (NASDAQ: OCUP) Right Now?
The 36-month beta value for OCUP is also noteworthy at 0.33. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for OCUP is 22.92M, and at present, short sellers hold a 6.89% of that float. The average trading volume of OCUP on May 02, 2024 was 221.04K shares.
OCUP’s Market Performance
OCUP stock saw a decrease of 19.87% in the past week, with a monthly decline of -5.15% and a quarterly a decrease of -32.60%. The volatility ratio for the week is 5.44%, and the volatility levels for the last 30 days are 6.46% for Ocuphire Pharma Inc (OCUP). The simple moving average for the past 20 days is 7.81% for OCUP’s stock, with a -37.98% simple moving average for the past 200 days.
OCUP Trading at -8.44% from the 50-Day Moving Average
After a stumble in the market that brought OCUP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.12% of loss for the given period.
Volatility was left at 6.46%, however, over the last 30 days, the volatility rate increased by 5.44%, as shares sank -1.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.29% lower at present.
During the last 5 trading sessions, OCUP rose by +20.85%, which changed the moving average for the period of 200-days by -54.31% in comparison to the 20-day moving average, which settled at $1.7055. In addition, Ocuphire Pharma Inc saw -38.87% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OCUP starting from Jhaveri Nirav S., who purchase 10,000 shares at the price of $2.10 back on Mar 21 ’24. After this action, Jhaveri Nirav S. now owns 150,000 shares of Ocuphire Pharma Inc, valued at $21,000 using the latest closing price.
SCHACHLE JOSEPH K, the Chief Operating Officer of Ocuphire Pharma Inc, purchase 2,000 shares at $2.05 during a trade that took place back on Mar 21 ’24, which means that SCHACHLE JOSEPH K is holding 2,000 shares at $4,100 based on the most recent closing price.
Stock Fundamentals for OCUP
Current profitability levels for the company are sitting at:
- -0.55 for the present operating margin
- 1.0 for the gross margin
The net margin for Ocuphire Pharma Inc stands at -0.51. The total capital return value is set at -0.21. Equity return is now at value -20.77, with -19.40 for asset returns.
Currently, EBITDA for the company is -10.56 million with net debt to EBITDA at 5.16. When we switch over and look at the enterprise to sales, we see a ratio of -0.27. The receivables turnover for the company is 8.17for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.35.
Conclusion
In summary, Ocuphire Pharma Inc (OCUP) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
